A new Duquesne University study using a nanomedicine that targets neuropathic pain at its source found that while males and females develop pain-like behavior to the same degree, the nanomedicine provided less relief for females.
The study marks the latest findings of the university's Chronic Pain Research Consortium (CPRC), a multidisciplinary collaboration by Dr. Jelena Janjic (founder/co-director) and Dr. John Pollock (co-director). A key component of this study is the application of the first inflammatory pain nanomedicine created by Dr. Janjic, which directly targets the source of pain.
Duquesne University has again been named to the 2022 Phi Theta Kappa (PTK) Transfer Honor Roll-a measure of excellence in supporting transfer student success.
As part of its methodology for developing the annual Transfer Honor Roll, PTK considers dozens of metrics and factors, including support and success of transfer students, campus life, admissions practices, cost and financial aid and degree completion. Duquesne is among 171 schools named to the 2022 Transfer Honor Roll.